A gastrointestinal Helicobacter pylori diagnosis and treatment system

Abstract

The present invention provides a gastrointestinal Helicobacter pylori diagnosis and treatment system, including a capsule endoscope, and also including a targeted probe that can specifically identify Helicobacter pylori and is used in conjunction with the capsule endoscope, wherein the capsule endoscope is equipped with a near-infrared light source module, an in vivo position control module, and an in vitro image receiving module, the position control module controls the position and lens direction of the capsule endoscope, and the image collected by the capsule endoscope is wirelessly transmitted to the in vitro image receiving module, and the image is analyzed, judged, and processed; the targeted probe that can specifically identify Helicobacter pylori includes at least one of urease antibodies and CagA antibodies targeting Helicobacter pylori or any combination thereof, and at least one of functional substances such as molecular contrast agents and light-absorbing and heat-generating substances is coupled to the antibody or any combination thereof. The probe can specifically identify and adsorb Helicobacter pylori in the gastrointestinal tract, realizing a new system for targeted imaging detection and treatment.

Description

Technical Field

[0001] The present invention relates to the field of medical devices, and in particular to a gastrointestinal Helicobacter pylori diagnosis and treatment system. Background Art

[0002] Helicobacter pylori is a Gram-negative bacillus with a spiral shape. It is not absolutely anaerobic, slightly aerobic, and has a strong survival ability. It can survive in a strong acid environment. Helicobacter pylori can cause gastrointestinal diseases such as gastritis, gastric ulcer, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma and gastric cancer. It is a carcinogen in the list of carcinogens published by the World Health Organization's International Agency for Research on Cancer. It is reported that the detection rate of Helicobacter pylori in patients with duodenal ulcers and gastric ulcers can reach 95%. In addition, about 75% of gastric cancers worldwide can be attributed to inflammation and damage caused by Helicobacter pylori. In addition to gastrointestinal diseases, some studies have shown that other diseases such as iron deficiency anemia, thrombocytopenia, eczema, acne, hypertension, coronary heart disease and periodontal disease are also related to Helicobacter pylori infection.

[0003] The infection rate of Helicobacter pylori varies around the world. In my country, it is generally believed that the infection rate of Helicobacter pylori can reach 50%-70%. Helicobacter pylori has a very high infection rate and contagiousness rate. However, the vast majority of infected people have no obvious symptoms and can only be found through relevant tests. However, the current popularity of routine testing for Helicobacter pylori is far from enough. The vast majority of patients with diseases such as gastric cancer and gastric ulcers only undergo relevant tests after they become ill and have obvious symptoms. When Helicobacter pylori is detected, the related gastrointestinal diseases caused by Helicobacter pylori are often in the middle and late stages. Therefore, early detection of Helicobacter pylori and early relevant treatment are of great significance for the prevention and control of gastrointestinal diseases such as gastric cancer, which can greatly reduce the incidence of gastrointestinal diseases such as gastric cancer and effectively improve the health level of residents.

[0004] Currently, there are three main systems for detecting Helicobacter pylori.

[0005] The first is an invasive test based on gastroscopy, which is to obtain gastric mucosal samples through an inserted gastroscope, and then take the samples out of the body for testing, such as through rapid urease test, gastric mucosal tissue section staining microscopy and bacterial culture method. This method has two disadvantages. First, this detection method will cause great discomfort to the person being tested both physically and psychologically, causing most people to be unwilling to take the initiative to check due to rejection of this method, thereby reducing the early detection rate of Helicobacter pylori. Second, this local sampling method can only reflect the situation of the sampled part, and cannot reflect the overall condition of the stomach. It has certain limitations and a certain rate of missed diagnosis.

[0006] The second is serum antibody testing. It is judged by detecting Helicobacter pylori antibodies in the patient's serum. This method also has certain defects. For example, serum antibodies have a certain time lag. After being infected with Helicobacter pylori, it takes a period of time, several months or even half a year, for the corresponding antibodies to be produced in the blood. After the patient is treated and cured, and Helicobacter pylori is eradicated in the body, the antibodies will still exist in the body for a long time. It often takes at least one year to turn from positive to negative. It lacks real-time performance and cannot reflect the current infection status.

[0007] The third is exhaled breath testing, including C13 and C14 methods. Patients only need to take urea capsules with isotope-labeled carbon atoms orally. If Helicobacter pylori exists in the stomach, it will decompose urea and produce isotope-labeled carbon dioxide. If it is detected in the exhaled breath, it means that Helicobacter pylori exists in the body. On the contrary, if isotope-labeled carbon dioxide is not detected in the exhaled breath, it means that Helicobacter pylori does not exist in the body. This method is non-invasive, does not cause pain to the person being examined, and can reflect the condition of the entire stomach. It is currently recognized as the most common and best way to examine Helicobacter pylori. However, this method also has certain disadvantages. The C14 method has a certain degree of radioactivity and will cause certain harm to the body. Therefore, this method is not suitable for the elderly, children, pregnant women and other groups. For the C13 method, if the patient takes antibiotics or other Helicobacter pylori-sensitive drugs one month before the examination, a false negative may occur.

[0008] Since infection with Helicobacter pylori will basically not heal itself, and eliminating Helicobacter pylori is one of the important measures to prevent gastrointestinal diseases such as gastric cancer, certain treatments are needed to kill Helicobacter pylori. The treatments for Helicobacter pylori mainly include triple therapy and quadruple therapy. In the past, it was mainly triple therapy, including proton pump inhibitors, plus two antibiotics, such as clarithromycin combined with amoxicillin, amoxicillin combined with levofloxacin, amoxicillin combined with furazolidone, etc. At present, this method has been eliminated and upgraded to quadruple therapy, including proton pump inhibitors, colloidal bismuth, and two antibiotics. However, due to the increasing rate of antibiotic resistance, the cure rate of this method is declining, and it will bring certain side effects, such as causing gastrointestinal microecological imbalance.

[0009] Therefore, it is necessary to provide an improved gastrointestinal Helicobacter pylori diagnosis and treatment system that can perform targeted detection and treatment of Helicobacter pylori with high specificity and accuracy without being invasive or having side effects, so as to solve the above-mentioned technical problems. Summary of the invention

[0010] The purpose of the present invention is to provide a gastrointestinal Helicobacter pylori diagnosis and treatment system.

[0011] Another object of the present invention is to provide an application of the above-mentioned gastrointestinal Helicobacter pylori diagnosis and treatment system.

[0012] The purpose of the present invention is achieved through the following scheme: A gastrointestinal Helicobacter pylori diagnosis and treatment system includes a capsule endoscope and a targeting probe that can specifically identify Helicobacter pylori and is used in conjunction with the capsule endoscope, wherein:

[0013] The capsule endoscope is equipped with a near-infrared light source module, an in-vivo position control module, and an in-vivo image receiving module. The position control module controls the position and lens direction of the capsule endoscope so that the capsule endoscope can perform an all-round scan of the gastrointestinal tract. The capsule endoscope collects gastrointestinal tract images and wirelessly transmits the collected images to the in-vivo image receiving module to analyze, judge, and process the images.

[0014] The targeting probe capable of specifically identifying Helicobacter pylori comprises at least one or any combination of antibodies targeting Helicobacter pylori such as urease antibody or CagA antibody, and the antibody is coupled with a functional molecular contrast agent and a light-absorbing heat-generating substance.

[0015] The present invention provides a non-invasive, side-effect-free, highly specific and highly accurate gastrointestinal Helicobacter pylori diagnosis and treatment system. After the targeted probe enters the gastrointestinal tract, it will specifically adsorb Helicobacter pylori, so that the functional substances on the probe will also be adsorbed on the Helicobacter pylori lesion site. The molecular contrast agent will emit fluorescence under the irradiation of the specific wavelength light source of the capsule endoscope, so that the Helicobacter pylori lesion site and the normal site and other lesion sites will be clearly distinguished, and the targeted imaging of the capsule endoscope will be realized. The capsule endoscope can wirelessly transmit a clear picture showing the scope of the lesion area to an image receiving module outside the body, thereby realizing the role of a specific targeted detector for gastrointestinal Helicobacter pylori. The light-absorbing and heat-generating substance will absorb light and convert it into heat energy under the irradiation of the specific wavelength light source of the near-infrared light illumination module of the capsule endoscope, so that the Helicobacter pylori lesion site will produce local high temperature, thereby killing the local Helicobacter pylori marked by the targeted probe, and realizing the role of a targeted photothermal ablation therapeutic device.

[0016] Based on the above scheme, the in vitro image receiving module includes display and storage functions, and establishes a deep learning-based model for receiving images sent by the capsule endoscope, displaying and storing images in real time, and performing intelligent processing and recognition of images through a trained deep learning-based model. When the presence of gastrointestinal Helicobacter pylori is found through image analysis, a reminder is issued to the physician.

[0017] Based on the above scheme, the targeted probe that can specifically identify Helicobacter pylori contains molecular contrast agents including near-infrared fluorescent probes, and light-absorbing and heat-generating substances including gold nanostars, so that they can be adsorbed onto the lesion site of Helicobacter pylori together with the probe.

[0018] Furthermore, the capsule endoscope is wirelessly powered by a battery or a wireless coil based on electromagnetic resonance inductive coupling, and collects gastrointestinal images autonomously or under external control through a preset program and wirelessly transmits them outside the body.

[0019] Based on the above scheme, the emission direction of the near-infrared light module is the same as the direction of the lens, and the wavelength range of near-infrared light is 780nm-2526nm, with a bias towards the 780nm end. Near-infrared light is an electromagnetic wave between visible light (VIS) and mid-infrared light (MIR). According to the definition of ASTM (American Society for Testing and Materials), it refers to electromagnetic waves with a wavelength range of 780 to 2526nm.

[0020] Based on the above scheme, the in-vivo position control module contains a small permanent magnet, so that the capsule endoscope can move autonomously in the body or move passively through external magnetic control, thereby controlling the posture and orientation of the capsule endoscope in the body to perform a full-scale scan of the gastrointestinal tract, or keep the position fixed when necessary.

[0021] Furthermore, the in vitro image receiving module is based on at least one peripheral device including a desktop computer, a laptop computer, a tablet computer, a mobile phone and an image hard disk storage device, and is used to receive images sent by the capsule endoscope, and to display and store the images in real time, and to analyze the images by a trained deep learning-based image processing model, and automatically issue a reminder when Helicobacter pylori is found.

[0022] The present invention provides an application of the gastrointestinal Helicobacter pylori diagnosis and treatment system in an inspection instrument:

[0023] The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains a near-infrared fluorescent probe. After a period of time, he takes a capsule endoscope. As the gastrointestinal tract moves, the capsule endoscope turns on the near-infrared light source module with the assistance of the position control module, and performs a comprehensive, specific examination of the gastrointestinal tract for Helicobacter pylori. When the physician actively discovers fluorescence or the extracorporeal image receiving module detects fluorescence after intelligent analysis and identification of the image and prompts the physician through a preset program, the physician controls the position control module to collect more comprehensive images of the lesion and records the lesion location. The capsule endoscope then continues to move with the peristalsis of the gastrointestinal tract and, with the assistance of the position control module, continues to detect the next position. The detection ends when the person being examined excretes the capsule from the body.

[0024] The present invention also provides an application of the gastrointestinal Helicobacter pylori diagnosis and treatment system in a therapeutic apparatus:

[0025] The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains gold nanostars and near-infrared fluorescent probes. After a period of time, he takes a capsule endoscope. As the gastrointestinal tract moves, the capsule endoscope turns on the near-infrared light source module with the assistance of the position control module, and performs a full-scale examination of the gastrointestinal tract. It collects images in real time and transmits them wirelessly to the outside of the body. When the physician actively discovers fluorescence or the external image receiving module detects fluorescence after intelligent analysis and identification of the image and prompts the physician through a preset program, the physician controls the internal position control module to continuously irradiate the lesion with a near-infrared light source until the local Helicobacter pylori marked by the probe is killed. Subsequently, the capsule endoscope continues to move with the peristalsis of the gastrointestinal tract, and with the assistance of the position control module, it continues to diagnose the next position until the capsule endoscope is excreted from the body, and the process ends.

[0026] Compared with the prior art, the invention has the following beneficial effects: the invention introduces a targeted probe that can specifically identify Helicobacter pylori, so that gastrointestinal Helicobacter pylori is directly exposed to the detection instrument - capsule endoscope, thereby achieving highly specific and accurate targeted positioning detection of gastrointestinal Helicobacter pylori without invasion and side effects, and can be used as a therapeutic instrument, providing a more complete new system for Helicobacter pylori inspection and treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 A schematic diagram of the composition of a targeted probe of the gastrointestinal Helicobacter pylori diagnosis and treatment system of the present invention;

[0028] Figure 2 A schematic diagram of the composition of the capsule endoscope of the present invention;

[0029] Figure 3 The system of the present invention is a detection flow chart of a detection instrument;

[0030] Figure 4 The treatment flow chart of the system of the present invention as a treatment device;

[0031] Description of the numbers in the figure:

[0032] 1——targeted probe;

[0033] 2——capsule endoscope; 201, 202——near infrared light source module one, two;

[0034] 203——in vivo position control module;

[0035] 3——External image receiving module;

[0036] 301——Image processing model based on deep learning;

[0037] 302 - Display

[0038] 303——Memory. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and cannot be understood as limiting the present invention.

[0040] Reference Figure 1 and Figure 2 As shown, the present invention provides a gastrointestinal Helicobacter pylori diagnosis and treatment system, comprising:

[0041] Figure 1 In the method, the targeting probe 1 that can specifically recognize Helicobacter pylori comprises at least one of antibodies targeting Helicobacter pylori such as urease antibody or CagA antibody or any combination thereof, and the antibody is coupled with a molecular contrast agent and a light-absorbing and heat-generating substance.

[0042] Figure 2 In the figure, the capsule endoscope 2 is equipped with near-infrared light source modules 1, 201, and 202, an in-vivo position control module 203, and an in-vivo image receiving module 3. In this embodiment, the in-vivo image receiving module 3 includes a deep learning-based model 301, a display 302, and a memory 303. The in-vivo image receiving module 3 is used to receive images sent by the capsule endoscope 2, display and store the images in real time, and perform intelligent processing and recognition on the images through the trained deep learning-based model 301. When the presence of gastrointestinal Helicobacter pylori is found through image analysis, a reminder is sent to the physician.

[0043] Among them, the targeting probe 1 that can specifically identify Helicobacter pylori contains a near-infrared fluorescent probe, so that the near-infrared fluorescent probe will also be adsorbed on the lesion site of Helicobacter pylori. Under the irradiation of the near-infrared light source module, the near-infrared fluorescent probe will emit fluorescence, so that the lesion site of Helicobacter pylori will have a clear optical distinction from the normal site and other lesion sites due to the presence of fluorescence. The fluorescent image showing the range of the Helicobacter pylori lesion area can be wirelessly transmitted to the external image receiving module 3 through the capsule endoscope 2, thereby realizing specific targeted detection of Helicobacter pylori in the gastrointestinal tract without invasion and side effects.

[0044] In order to achieve the purpose of specific treatment, a light-absorbing and heat-generating substance - gold nanostars is added to the targeted probe 1 that can specifically identify Helicobacter pylori, so that it can be adsorbed to the lesion site of Helicobacter pylori together with the targeted antibody and the near-infrared fluorescent probe. Under the irradiation of the near-infrared light source of the capsule endoscope 2, it will absorb light and then convert it into heat energy, causing local high temperature to be generated in the lesion site of Helicobacter pylori, thereby killing the local Helicobacter pylori marked by the probe, realizing specific targeted photothermal ablation treatment without invasion and side effects.

[0045] Among them, the capsule endoscope 2 can be powered by a battery or wireless power supply such as a wireless coil based on electromagnetic resonance inductive coupling, and can collect gastrointestinal images autonomously or under external control through a preset program and wirelessly transmit them to the outside of the body. The light emitted by the near-infrared light module is near-infrared light, and the direction is the same as the direction of the lens. The wavelength of near-infrared light is near the 780nm endpoint in the range of 780nm-2526nm. The penetration depth of near-infrared light in this band in biological tissue is relatively large, which can reach 10cm, and the fluorescence in this band is less affected by the background of biological tissue, and can be effectively used to excite near-infrared fluorescent probes to emit fluorescence and gold nanostars to generate heat.

[0046] The capsule endoscope in vivo position control module 203 contains a small permanent magnet, so that the capsule endoscope 2 can perform autonomous movement such as autonomous mechanical movement in the body, or can be passively moved by external magnetic control. Preferably, through magnetic control, a large permanent magnet or electromagnetic field can be used externally to maintain induction with the permanent magnet in the capsule endoscope, thereby controlling the posture and orientation of the capsule endoscope 2 in the body, so that the capsule endoscope can perform an all-round scan of the gastrointestinal tract, or when necessary, such as fixed-point imaging and photothermal ablation treatment, the position can be kept basically unchanged.

[0047] The in vitro image receiving module 3 is used to receive images sent by the capsule endoscope, and can display and store images in real time. It can be based on a variety of peripherals, such as desktop computers, laptops, tablet computers, mobile phones and image hard disk storage devices, etc. This embodiment selects a desktop computer and is trained with an image processing model 301 based on deep learning. It can automatically identify gastrointestinal fluorescence images and determine the location and approximate area of ​​Helicobacter pylori. When the presence of Helicobacter pylori is found by analyzing the image, an alert is automatically issued.

[0048] The gastrointestinal Helicobacter pylori diagnosis and treatment system of this embodiment is used as the detection process of the detector:

[0049] A check flow chart is as follows Figure 3As shown. The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains a near-infrared fluorescent probe. After a period of time, the capsule endoscope is taken. As the gastrointestinal tract moves, the capsule endoscope, with the assistance of the position control module, turns on the near-infrared light source to conduct a comprehensive and specific inspection of the gastrointestinal tract for Helicobacter pylori to check whether fluorescence appears. When the physician actively discovers fluorescence or the in vitro image receiving module intelligently analyzes and identifies the image and discovers fluorescence and prompts the physician through a preset program, the physician controls the position control module to collect more comprehensive images of the lesion. When enough images are collected to fully reflect the lesion, the lesion location is recorded. The capsule endoscope then continues to move with the peristalsis of the gastrointestinal tract, and with the assistance of the position control module, it continues to detect the next position. When the person being examined expels the capsule from the body, the test is completed.

[0050] The operation flow of the gastrointestinal Helicobacter pylori diagnosis and treatment system of this embodiment as a therapeutic device is as follows: Figure 4 As shown:

[0051] The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains gold nanostars and near-infrared fluorescent probes. After a period of time, the capsule endoscope is taken. As the gastrointestinal tract moves, the capsule endoscope turns on the near-infrared light source with the assistance of the position control module to conduct a full-scale inspection of the gastrointestinal tract, collect images in real time and transmit them wirelessly to the outside of the body. When the physician actively discovers fluorescence or the external image receiving module intelligently analyzes and identifies the image and detects fluorescence and prompts the physician through a preset program, the physician controls the position control system to continuously irradiate the lesion with a near-infrared light source until the local Helicobacter pylori marked by the probe is killed. The capsule endoscope then continues to move with the peristalsis of the gastrointestinal tract, and with the assistance of the position control module, it continues to diagnose the next position. When the person being examined expels the capsule from the body, the test is completed.

[0052] The above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A gastrointestinal Helicobacter pylori diagnosis and treatment system, comprising a capsule endoscope, characterized in that: It also includes a targeted probe used in conjunction with a capsule endoscope and capable of specifically identifying Helicobacter pylori, wherein: The capsule endoscope is equipped with a near-infrared light source module, an in-vivo position control module and an in-vitro image receiving module. The position control module controls the position and lens direction of the capsule endoscope. The image collected by the capsule endoscope is wirelessly transmitted to the in-vitro image receiving module to analyze, judge and process the image. The targeting probe that can specifically identify Helicobacter pylori includes at least one of urease antibodies and CagA antibodies targeting Helicobacter pylori or any combination thereof, a near-infrared fluorescent probe is arranged on the antibody as a coupled molecular contrast agent, and a gold nanostar is arranged as a light-absorbing and heat-generating substance.

2. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1, characterized in that: The in vitro image receiving module includes display and storage functions, and has established a deep learning-based model for receiving images sent by a capsule endoscope, displaying and storing images in real time, and performing intelligent processing and recognition of images through a trained deep learning-based model. When the presence of gastrointestinal Helicobacter pylori is found through image analysis, a reminder is issued to the physician.

3. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1, characterized in that: The targeted probe that can specifically identify Helicobacter pylori contains molecular contrast agents including near-infrared fluorescent probes, and light-absorbing and heat-generating substances including gold nanostars, so that they can be adsorbed onto the lesion site of Helicobacter pylori together with the probe.

4. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1 or 2, characterized in that: The capsule endoscope is wirelessly powered by a battery or a wireless coil based on electromagnetic resonance inductive coupling, and collects gastrointestinal images autonomously or under external control through a preset program and wirelessly transmits them outside the body.

5. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1, characterized in that: The near-infrared light source module comprises near-infrared light source module one and near-infrared light source module two. The emission direction of the near-infrared light source module is consistent with the direction of the lens. The wavelength range of the near-infrared light is 780nm-2526nm, with a bias towards the 780nm end.

6. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1, characterized in that: The in-body position control module contains a small permanent magnet, which enables the capsule endoscope to move autonomously in the body or passively move by external magnetic control, thereby controlling the posture and orientation of the capsule endoscope in the body to perform a full-scale scan of the gastrointestinal tract or keep the position fixed when necessary.

7. The gastrointestinal Helicobacter pylori diagnosis and treatment system according to claim 1 or 2, characterized in that: The in vitro image receiving module is based on at least one peripheral device including a desktop computer, a laptop computer, a tablet computer, a mobile phone and an image hard disk storage device, and is used to receive images sent by a capsule endoscope, and to display and store images in real time. It also analyzes images by using an image processing model trained based on deep learning, and automatically issues a reminder when Helicobacter pylori is found.

8. Use of the gastrointestinal Helicobacter pylori diagnosis and treatment system according to any one of claims 1 to 7 in an inspection instrument, characterized in that: The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains a near-infrared fluorescent probe that emits fluorescence when illuminated by a near-infrared light source. After a period of time, the person then takes a capsule endoscope. As the gastrointestinal tract moves, the capsule endoscope turns on the near-infrared light source module with the assistance of the position control module, and performs a comprehensive, specific examination of the gastrointestinal tract for Helicobacter pylori. When the physician actively discovers fluorescence or the in vitro image receiving module intelligently analyzes and identifies the image and detects fluorescence and prompts the physician through a preset program, the physician controls the position control module to collect more comprehensive images of the lesion and records the lesion location. The capsule endoscope then continues to move with the peristalsis of the gastrointestinal tract and, with the assistance of the position control module, continues to detect the next position. The detection ends when the person being examined excretes the capsule from the body.

9. Use of the gastrointestinal Helicobacter pylori diagnosis and treatment system according to any one of claims 1 to 7 in a therapeutic apparatus, characterized in that: The person being examined first takes a targeted probe that can specifically identify Helicobacter pylori. The targeted probe contains gold nanostars and near-infrared fluorescent probes. After a period of time, he takes a capsule endoscope. As the gastrointestinal tract moves, the capsule endoscope turns on the near-infrared light source module with the assistance of the position control module, and performs a full-scale examination of the gastrointestinal tract. It collects images in real time and transmits them wirelessly to the outside of the body. When the physician actively discovers fluorescence or the external image receiving module detects fluorescence after intelligent analysis and identification of the image and prompts the physician through a preset program, the physician controls the internal position control module to continuously irradiate the lesion with a near-infrared light source until the local Helicobacter pylori marked by the probe is killed. Subsequently, the capsule endoscope continues to move with the peristalsis of the gastrointestinal tract, and with the assistance of the position control module, it continues to diagnose the next position until the capsule endoscope is excreted from the body, and the process ends.

Images